Loading clinical trials...
Loading clinical trials...
Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy - Employing Optimized (Hypofractionated) Radiotherapy to Foster Durvalumab Efficacy
Conditions
Interventions
Durvalumab Injection [Imfinzi]
Thoracic Radiotherapy (TRT) conventionally
+1 more
Locations
14
Germany
Universitätsklinikum Aachen
Aachen, Germany
DRK Kliniken Berlin-Mitte
Berlin, Germany
Kliniken der Stadt Köln gGmbH, Lungenklinik Merheim
Cologne, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Onkodok GmbH
Gütersloh, Germany
Thoraxklinik am Universitätsklinikum Heidelberg
Heidelberg, Germany
Start Date
May 20, 2020
Primary Completion Date
January 21, 2026
Completion Date
January 21, 2026
Last Updated
March 27, 2026
NCT06945484
NCT05718297
NCT06614231
NCT05311709
NCT01470716
NCT05177497
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions